Bristol Myers turns to Oxford Biomedica for CAR-T manufacturing

By Vassia Barba

- Last updated on GMT

(Image: Getty/tadamichi)
(Image: Getty/tadamichi)

Related tags Bristol Myers Squibb Bristol-myers squibb CAR-T

Oxford Biomedica set to receive up to $96m to support the development of Juno’s CAR-T therapies.

The agreement will see Oxford Biomedica partner with Juno Therapeutics, a chimeric antigen receptor (CAR)-T therapy developer, acquired​ in 2018 by Celgene, which is, in turn, now a Bristol Myers Squibb company​.

Under a non-exclusive license, Oxford Biomedica will provide Juno with access to its LentiVector platform, supporting the development of the latter’s CAR-T and T cell receptor therapeutics (TCR-T) programs.

Moreover, the companies have agreed to a five-year long clinical supply of lentiviral vectors for Juno’s development projects, with the potential for further extension of the agreement.

Per the financial terms, Oxford Biomedica will receive an upfront cash payment of $10m (€9.3m); up to $86m (€80.1m) dependent on development and regulatory milestones; and up to $131m (€122.1m) in sales-based milestone payments.

The manufacturing work has begun at Oxford Biomedica's commercial manufacturing center located in Oxford, UK, with the manufacturer working on four undisclosed projects.

Juno and BMS are putting significant efforts​ into optimizing manufacturing for CAR-T development projects, since a potential approval would see any product arrive as the third to market, after the commercialization of Novartis’ Kymriah (tisagenlecleucel), and Gilead’s Yescarta (axicabtagene ciloleucel).

In December 2019, BMS won a patent infringement suit​ against Gilead on Yescarta, which saw the latter’s subsidiary, Kite, ordered to pay Juno $752m – though Juno then requested the judge to raise that penalty to $1.5bn.

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Related suppliers

Follow us

Products

View more

Webinars